COVIran Barekat
COVIran Barekat (Persian: کووایران برکت) is a COVID-19 vaccine developed in Iran by Shifa Pharmed Industrial Group, a subsidiary of the Barkat Pharmaceutical Group. It is an inactivated virus-based vaccine. Iranian authorities have authorized its emergency use. This makes it the first locally developed COVID-19 vaccine to be approved for emergency use in the Middle East.
A vial of COVIran Barakat | |
| Vaccine description | |
|---|---|
| Target | SARS-CoV-2 |
| Vaccine type | Inactivated |
| Clinical data | |
| Other names | BIV1-CovIran COVIran Barakat COVIran Barkat کووایران برکت |
| Routes of administration | Intramuscular |
| ATC code |
|
| Legal status | |
| Legal status |
Full and emergency authorizations Full list of COVIran Barekat authorizations |
Officials in charge say they are in the process to publish the results of the clinical trials in a peer-reviewed journal. The interim results of the phases 1 and 2 trials showed 93.5% (95% CI, 88.4–99.6%) of the receivers of the vaccine have produced neutralizing antibodies against SARS-CoV-2. Those results have not been peer-reviewed and describe the immunogenicity of the vaccine and not its efficacy. On 3 March 2022, peer-reviewed results have been published in the Clinical Microbiology and Infection.
As of February 27, 2022, approximately 60 million doses have been produced according to Shifa Pharmed's CEO. and the annual production capacity of this vaccine has reached 350 million doses. Multiple Iranian personalities have received the vaccine, including the Supreme Leader, Ali Khamenei and the President, Ebrahim Raisi.
A version of the vaccine based on the Omicron variant and named CovIran Barkat Plus is in development and studied to be given as a third dose.